A decision modeling study found that TissueCypher-guided care could increase appropriate treatment decisions for Barrett’s esophagus patients, including earlier escalation for non-dysplastic patients who later progress to high-grade dysplasia or cancer.
Key Investor Takeaways
- Castle Biosciences (NASDAQ:CSTL) reported a TissueCypher study showing appropriate Barrett’s esophagus management increased from 59.8% to 75.3% when test results were incorporated into modeled clinical decisions.
- Among patients who progressed to high-grade dysplasia or esophageal adenocarcinoma, appropriate escalation increased from 50.5% to 66.3%, representing a modeled 31.9% reduction in undertreatment.
- The largest change occurred among non-dysplastic Barrett’s esophagus patients who later progressed, where appropriate escalation nearly doubled from 30.4% to 56.9%.
- TissueCypher-guided decisions also produced a modeled 41.7% reduction in overtreatment among patients who did not progress.
- The findings support the test’s potential clinical utility, but the analysis was based on decision modeling rather than a prospective study measuring changes in actual patient management or outcomes.
Why CSTL Stock Is in Focus
Castle Biosciences announced a decision modeling study evaluating whether its TissueCypher Barrett’s Esophagus test could improve management decisions by identifying patients at greater or lower risk of disease progression.
Researchers modeled clinical decisions with and without TissueCypher guidance using pooled data from 699 patients across five previously published validation studies. Patients had known progression or non-progression outcomes and included those with non-dysplastic Barrett’s esophagus, indefinite for dysplasia and low-grade dysplasia.
Across the full population, appropriate management increased from 59.8% without TissueCypher guidance to 75.3% with the test, with a reported P value below 0.001.
Among patients who ultimately progressed to high-grade dysplasia or esophageal adenocarcinoma, appropriate escalation to short-interval surveillance or endoscopic eradication therapy increased from 50.5% to 66.3%.
The effect was particularly notable among patients initially diagnosed with non-dysplastic Barrett’s esophagus who subsequently progressed. Appropriate escalation increased from 30.4% to 56.9% in the model.
Why This Matters for Investors
The study provides additional evidence supporting the potential clinical utility of TissueCypher, rather than focusing solely on its ability to predict disease progression.
That distinction could matter for Castle Biosciences because a diagnostic test’s role in patient care depends partly on whether its results can meaningfully influence clinical decisions. The modeling suggests TissueCypher could potentially address both sides of Barrett’s esophagus management: identifying higher-risk patients for more intensive care while reducing unnecessary procedures among lower-risk patients.
Non-dysplastic Barrett’s esophagus represents a particularly relevant population. According to the release, these patients account for approximately 89% of those undergoing Barrett’s surveillance in the U.S., while roughly half of patients who eventually develop cancer were initially diagnosed with non-dysplastic disease.
The results nevertheless require an important qualification. This was a decision-tree modeling study using data from previous validation studies. It therefore demonstrates how TissueCypher could have changed management decisions under the model, rather than showing prospectively that its use changed physician behavior or improved patient outcomes.
For investors assessing TissueCypher’s commercial positioning, further evidence connecting risk classification with real-world clinical decisions could help establish the test’s role within Barrett’s esophagus care.
What to Watch Next
The study is set to be published in the Annals of Gastroenterology, adding to the clinical evidence supporting TissueCypher.
Investors can watch for additional prospective or real-world studies evaluating whether TissueCypher changes clinical management and patient outcomes, particularly within the large non-dysplastic Barrett’s esophagus population.
Evidence of broader clinical adoption or other developments demonstrating how the test is incorporated into routine surveillance and treatment decisions could provide further indications of its commercial relevance for Castle Biosciences.